<div class="headers"><div>FIGURE 1 Overall mortality in the four treatment groups (placebo, fluticasone furoate (FF), vilanterol (VI) and FF/VI) according to previous treatment use. a) Those receiving no inhaled pre-treatment maintenance medication; b) those on inhaled corticosteroids and long-acting bronchodilators as previous treatment use. FIGURE 2 Risk of moderate/severe exacerbations in the four treatment groups (placebo, fluticasone furoate (FF), vilanterol (VI) and FF/VI) according to previous treatment use. a) Those receiving no inhaled pre-treatment maintenance medication; b) those on inhaled corticosteroids and long-acting bronchodilators as previous treatment use. COPD: chronic obstructive pulmonary disease. Figure S1.
Overall mortality in the four treatment groups (placebo, fluticasone furoate, vilanterol, and combined fluticasone furoate and vilanterol) according to previous treatment use. Panel A shows those ICS alone as previous treatment use and Panel B shows those on LABD alone as 
previous treatment use.
Figure S2.
Risk of moderate/severe exacerbations in the four treatment groups (placebo, fluticasone furoate, vilanterol, and combined fluticasone furoate and vilanterol) according to previous treatment use. Panel A shows those ICS alone as previous treatment use and Panel B shows those 
on LABD alone as previous treatment use.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'></td>
<td style='border-top: 2px solid grey; text-align: left;'><p class="">a) Those receiving no inhaled pre-treatment maintenance medication</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p class=""> b) those on inhaled corticosteroids and long-acting bronchodilators as previous treatment use.</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p class="">Previous ICS alone</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p class="">Previous LABD alone</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p class="">P-interaction</p></td>
</tr>
<tr>
<td style='text-align: left;'><p class="">Overall mortality</p></td>
<td style='text-align: left;'><p class="">FF/VI –2% (95% CI –29–20%)</p></td>
<td style='text-align: left;'><p class="">FF/VI 35% (95% CI 11–52%)</p></td>
<td style='text-align: left;'><p class="">FF/VI 1% (-126%, 57%)</p></td>
<td style='text-align: left;'><p class="">FF/VI 5% (-61%, 44%)</p></td>
<td style='text-align: left;'><p class="">0.44</p></td>
</tr>
<tr>
<td style='text-align: left;'><p class="">Overall mortality</p></td>
<td style='text-align: left;'><p class="">  FF 4% (95% CI –22–24%)</p></td>
<td style='text-align: left;'><p class="">  FF 24% (95% CI –3–44%)</p></td>
<td style='text-align: left;'><p class="">FF -46% (-211%, 32%)</p></td>
<td style='text-align: left;'><p class="">FF 7% (-60%, 45%)</p></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p class="">Overall mortality</p></td>
<td style='text-align: left;'><p class="">  VI –7% (95% CI –35–15%)</p></td>
<td style='text-align: left;'><p class="">  VI 19% (95% CI –9–40%)</p></td>
<td style='text-align: left;'><p class="">VI -35% (-185%, 3%)</p></td>
<td style='text-align: left;'><p class="">VI 26% (-29%, 58%)</p></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p class="">Risk of moderate/severe exacerbations </p></td>
<td style='text-align: left;'><p class=""> FF/VI 20% (95% CI 10–29%)</p></td>
<td style='text-align: left;'><p class="">FF/VI 23% (95% CI 12–34%)</p></td>
<td style='text-align: left;'><p class="">FF/VI 12% (-32%, 42%)</p></td>
<td style='text-align: left;'><p class="">FF/VI 23% (2%, 39%)</p></td>
<td style='text-align: left;'><p class="">0.45</p></td>
</tr>
<tr>
<td style='text-align: left;'><p class="">Risk of moderate/severe exacerbations </p></td>
<td style='text-align: left;'><p class="">  FF 5% (95% CI –7–15%)</p></td>
<td style='text-align: left;'><p class="">  FF –1% (95% CI –15–12%)</p></td>
<td style='text-align: left;'><p class="">FF 11% (-34%, 41%)</p></td>
<td style='text-align: left;'><p class="">FF    3% (-23%, 23%)</p></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">Risk of moderate/severe exacerbations </p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">  VI 16% (95% CI 5–25%)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">  VI 1% (95% CI –13–14%)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">VI -18% (-72%, 19%)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">VI    12% (-10%, 30%)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'></td>
</tr>
</tbody>
</table>
